Capricor Therapeutics (NASDAQ:CAPR) Given Buy Rating at Maxim Group

Maxim Group reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note released on Tuesday, Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $20.00.

Capricor Therapeutics Stock Down 2.5 %

NASDAQ:CAPR opened at $4.99 on Tuesday. The stock has a market cap of $159.58 million, a price-to-earnings ratio of -5.74 and a beta of 3.92. The company’s 50 day moving average price is $4.36 and its 200-day moving average price is $5.18. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. As a group, sell-side analysts anticipate that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CAPR. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the 2nd quarter worth approximately $426,000. Renaissance Technologies LLC increased its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC increased its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. Rhumbline Advisers purchased a new position in Capricor Therapeutics during the second quarter valued at $147,000. Finally, Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.